KR100618063B1 - 1-옥사-3,9-디아자-스피로[5.5]운데칸-2-온 유도체, 및 이의 뉴로키닌 수용체 길항제로서의 용도 - Google Patents

1-옥사-3,9-디아자-스피로[5.5]운데칸-2-온 유도체, 및 이의 뉴로키닌 수용체 길항제로서의 용도 Download PDF

Info

Publication number
KR100618063B1
KR100618063B1 KR1020037014713A KR20037014713A KR100618063B1 KR 100618063 B1 KR100618063 B1 KR 100618063B1 KR 1020037014713 A KR1020037014713 A KR 1020037014713A KR 20037014713 A KR20037014713 A KR 20037014713A KR 100618063 B1 KR100618063 B1 KR 100618063B1
Authority
KR
South Korea
Prior art keywords
formula
oxa
spiro
phenyl
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037014713A
Other languages
English (en)
Korean (ko)
Other versions
KR20030094405A (ko
Inventor
카이하이-잉
딜론미카엘패트릭
갤리귀도
고에글러애닉
콜체비스키사비네
무진스키-바르시다운매리
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20030094405A publication Critical patent/KR20030094405A/ko
Application granted granted Critical
Publication of KR100618063B1 publication Critical patent/KR100618063B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020037014713A 2001-05-14 2002-05-06 1-옥사-3,9-디아자-스피로[5.5]운데칸-2-온 유도체, 및 이의 뉴로키닌 수용체 길항제로서의 용도 Expired - Fee Related KR100618063B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01111644.9 2001-05-14
EP01111644 2001-05-14
PCT/EP2002/004935 WO2002092604A1 (en) 2001-05-14 2002-05-06 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor

Publications (2)

Publication Number Publication Date
KR20030094405A KR20030094405A (ko) 2003-12-11
KR100618063B1 true KR100618063B1 (ko) 2006-08-30

Family

ID=8177412

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037014713A Expired - Fee Related KR100618063B1 (ko) 2001-05-14 2002-05-06 1-옥사-3,9-디아자-스피로[5.5]운데칸-2-온 유도체, 및 이의 뉴로키닌 수용체 길항제로서의 용도

Country Status (17)

Country Link
US (1) US6599900B2 (enExample)
EP (1) EP1390372B1 (enExample)
JP (1) JP4056887B2 (enExample)
KR (1) KR100618063B1 (enExample)
CN (1) CN1264847C (enExample)
AR (1) AR033631A1 (enExample)
AT (1) ATE401333T1 (enExample)
AU (1) AU2002342238B2 (enExample)
BR (1) BR0209604A (enExample)
CA (1) CA2447329C (enExample)
DE (1) DE60227657D1 (enExample)
DK (1) DK1390372T3 (enExample)
ES (1) ES2310206T3 (enExample)
MX (1) MXPA03010321A (enExample)
PT (1) PT1390372E (enExample)
WO (1) WO2002092604A1 (enExample)
ZA (1) ZA200308535B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1716156A2 (en) * 2004-02-10 2006-11-02 F.Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
ES2346147T3 (es) * 2005-03-03 2010-10-11 Janssen Pharmaceutica Nv Derivados de oxa-diaza-espiro-(5.5)-undecanona sustituidos y su uso como antagonistas de las neuroquininas.
NZ556628A (en) 2005-03-08 2009-09-25 Janssen Pharmaceutica Nv Diaza-spiro-[4.4]-nonane derivatives as neurokinin (NK1) antagonists
US7470684B2 (en) 2007-01-03 2008-12-30 Hoffmann-La Roche Inc. Spiropiperidine derivatives as NK3 antagonists
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
BRPI0809646A2 (pt) 2007-03-29 2014-09-23 Hoffmann La Roche Compostod antivirais heterocíclicos
MX375424B (es) 2015-07-31 2025-03-06 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl
MX2019008626A (es) 2017-01-20 2019-09-19 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
JP2020506903A (ja) 2017-01-23 2020-03-05 ファイザー・インク Ｍａｇｌ阻害薬としての複素環式スピロ化合物
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2131021B (en) * 1982-11-24 1985-12-18 Erba Farmitalia Antipsychotic benzoxazines
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
WO1997011940A1 (en) * 1995-09-29 1997-04-03 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation

Also Published As

Publication number Publication date
KR20030094405A (ko) 2003-12-11
US6599900B2 (en) 2003-07-29
BR0209604A (pt) 2004-03-23
CA2447329C (en) 2009-07-28
AU2002342238B2 (en) 2007-01-25
ES2310206T3 (es) 2009-01-01
EP1390372A1 (en) 2004-02-25
CN1507449A (zh) 2004-06-23
DE60227657D1 (de) 2008-08-28
CN1264847C (zh) 2006-07-19
AR033631A1 (es) 2003-12-26
DK1390372T3 (da) 2008-09-15
US20030004163A1 (en) 2003-01-02
CA2447329A1 (en) 2002-11-21
WO2002092604A1 (en) 2002-11-21
JP2004534758A (ja) 2004-11-18
PT1390372E (pt) 2008-08-25
MXPA03010321A (es) 2004-02-17
JP4056887B2 (ja) 2008-03-05
ATE401333T1 (de) 2008-08-15
EP1390372B1 (en) 2008-07-16
ZA200308535B (en) 2005-01-31

Similar Documents

Publication Publication Date Title
KR100518198B1 (ko) 뉴로키닌 수용체 길항제로서의 1,3,8-트라이아자-스피로[4.5]데칸-4-온 유도체
US20240366639A1 (en) Heterocyclic glp-1 agonists
US6245773B1 (en) 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
DE3851597T2 (de) Lactamderivate.
EP4699609A2 (en) Heterocyclic glp-1 agonists
WO2022078380A1 (en) Heterocyclic glp-1 agonists
TW202142538A (zh) 雜環ｇｌｐ－１促效劑
AU688168B2 (en) 5-HTht1f mediated inhibition of neurogenic meningeal extravasation
CN101657418B (zh) 作为nk1/nk3受体双重拮抗剂的吡咯烷衍生物
CA3048376A1 (en) Bmp-signal-inhibiting compound
KR20070063562A (ko) 치환 디피페리딘 ｃｃｒ２ 길항제
HU228128B1 (hu) Tachikinin-receptor antagonista hatású 1-(1,2-diszubsztituált piperidinil)-4-szubsztituált piperidinszármazékok
JP2004511544A (ja) 化合物
WO1999032489A1 (en) Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
KR20030094405A (ko) 1-옥사-3,9-디아자-스피로[5.5]운데칸-2-온 유도체, 및 이의 뉴로키닌 수용체 길항제로서의 용도
KR20200100111A (ko) 바소프레신 v1a 수용체 길항제로서 트리아졸로벤즈아제핀
JP2010540524A (ja) ガンマセクレターゼモジュレーター
EP0696194B1 (en) Use of indole derivatives as 5ht1 antagonists
AU2002342238A1 (en) 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor
WO1997016192A1 (en) Muscarine antagonists
EP1296987B1 (en) Compounds for treating impaired fundic relaxation
US5360800A (en) Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
EP1513831B1 (en) Novel compounds, their use and preparation
HRP20010869A2 (en) Pyrrolidinyl, piperidinyl or homopiperidinyl substituted (benzodioxan, benzofuran or benzopyran) derivatives
MXPA01012330A (es) Derivados (benzodioxano, benzofurano o benzopirano) aminoalquil sustituidos.

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20090709

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100824

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100824

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000